| scholarly article | Q13442814 |
| P50 | author | Daphne Haas-Kogan | Q95227712 |
| P2093 | author name string | C David James | |
| Christopher S Ward | |||
| Sabrina M Ronen | |||
| Humsa S Venkatesh | |||
| Myriam M Chaumeil | |||
| P2860 | cites work | Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1 | Q24320257 |
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR | Q24683340 | ||
| Malignant astrocytic glioma: genetics, biology, and paths to treatment | Q29618156 | ||
| Tumor cell metabolism: cancer's Achilles' heel | Q29619809 | ||
| Regulation of translation initiation by FRAP/mTOR | Q29620398 | ||
| CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. | Q30447832 | ||
| Multivoxel magnetic resonance spectroscopy of brain tumors | Q30794053 | ||
| Studies of human tumors by MRS: a review | Q30833628 | ||
| Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo | Q31009512 | ||
| Recent advances in therapy for glioblastoma | Q33538475 | ||
| The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. | Q33959529 | ||
| HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression | Q33968465 | ||
| Applications of magnetic resonance in model systems: cancer therapeutics | Q33995811 | ||
| Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors | Q34132735 | ||
| Implementation of 3 T lactate-edited 3D 1H MR spectroscopic imaging with flyback echo-planar readout for gliomas patients | Q34440284 | ||
| 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2 | Q34989144 | ||
| Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy | Q35891675 | ||
| Hypoxia signalling in cancer and approaches to enforce tumour regression | Q36488739 | ||
| Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1- 13C]pyruvate and 13C magnetic resonance spectroscopic imaging | Q36949701 | ||
| Deregulated signalling networks in human brain tumours | Q37625147 | ||
| PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel | Q37678179 | ||
| Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma | Q38742022 | ||
| Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading | Q39301749 | ||
| Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging | Q39540514 | ||
| Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma | Q39739265 | ||
| Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR. | Q39892965 | ||
| A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity | Q40028705 | ||
| Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria | Q40044872 | ||
| Alterations of choline phospholipid metabolism in ovarian tumor progression | Q40360938 | ||
| In vivo 31P MRS of experimental tumours | Q40735412 | ||
| Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. | Q40791953 | ||
| Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model | Q41712416 | ||
| Analysis of mTOR inhibition-involved pathway in ovarian clear cell adenocarcinoma | Q41895705 | ||
| Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy | Q41939336 | ||
| Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. | Q42415330 | ||
| Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel | Q43491437 | ||
| Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors | Q43570065 | ||
| Efficient 1H to 31P polarization transfer on a clinical 3T MR system. | Q46230958 | ||
| Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells | Q46908003 | ||
| Hypoxic Regulation of Lactate Dehydrogenase A | Q57378005 | ||
| Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake | Q68259711 | ||
| Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy | Q71843758 | ||
| Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment | Q77707829 | ||
| Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy | Q78108523 | ||
| In vivo 13 carbon metabolic imaging at 3T with hyperpolarized 13C-1-pyruvate | Q80691642 | ||
| A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16 | Q83350735 | ||
| P433 | issue | 3 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 315-325 | |
| P577 | publication date | 2011-12-12 | |
| P1433 | published in | Neuro-Oncology | Q15724471 |
| P1476 | title | Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma | |
| P478 | volume | 14 |
| Q27009286 | A review of responsive MRI contrast agents: 2005-2014 |
| Q28830010 | Advances in Magnetic Resonance Imaging Contrast Agents for Biomarker Detection |
| Q36633528 | Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells |
| Q38773520 | Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI. |
| Q60935363 | Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma |
| Q35150284 | Cellular protection using Flt3 and PI3Kα inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity |
| Q38947387 | Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. |
| Q37697784 | Characterization of metabolites in infiltrating gliomas using ex vivo ¹H high-resolution magic angle spinning spectroscopy |
| Q39817583 | Characterization of the serum metabolome following radiation treatment in patients with high-grade gliomas |
| Q35013696 | Chemical mapping of the colorectal cancer microenvironment via MALDI imaging mass spectrometry (MALDI-MSI) reveals novel cancer-associated field effects |
| Q64982984 | Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled-choline incorporation. |
| Q41336182 | Commentary: Targeting LDH enzymes with a stiripentol analog to treat epilepsy |
| Q26853308 | Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients |
| Q27021691 | Detecting enzyme activities with exogenous MRI contrast agents |
| Q44844537 | Differentiating diffuse World Health Organization grade II and IV astrocytomas with ex vivo magnetic resonance spectroscopy |
| Q38729363 | Differentiating inflamed and normal lungs by the apparent reaction rate constants of lactate dehydrogenase probed by hyperpolarized (13)C labeled pyruvate |
| Q38335029 | Effects of deranged metabolism on epigenetic changes in cancer |
| Q49393542 | Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models. |
| Q92035048 | Ex vivo metabolite profiling of paediatric central nervous system tumours reveals prognostic markers |
| Q90611895 | HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI |
| Q37081252 | Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. |
| Q92137259 | Hyperpolarized 13C MRI: State of the Art and Future Directions |
| Q37588737 | Hyperpolarized NMR probes for biological assays. |
| Q38990221 | Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma |
| Q55261716 | Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas. |
| Q38680891 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells |
| Q47853442 | In vivo Metabolic Profiles as Determined by (31)P and short TE (1)H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas |
| Q91817106 | Insights into the Chemical Biology of Childhood Embryonal Solid Tumors by NMR-Based Metabolomics |
| Q31154376 | Interrogating IDH Mutation in Brain Tumor: Magnetic Resonance and Hyperpolarization. |
| Q31136705 | Interrogating Metabolism in Brain Cancer. |
| Q38840489 | Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics |
| Q38969526 | Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma |
| Q43296499 | MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy |
| Q31137181 | MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy |
| Q36918102 | MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. |
| Q39007170 | MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition |
| Q31015256 | Magnetic Resonance (MR) Metabolic Imaging in Glioma. |
| Q92020287 | Magnetic Resonance Imaging Is More Sensitive Than PET for Detecting Treatment-Induced Cell Death-Dependent Changes in Glycolysis |
| Q49829513 | Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomics-Relevance to Glioma. |
| Q99721505 | Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer |
| Q58086874 | Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma |
| Q36713482 | Metabolic response of glioma to dichloroacetate measured in vivo by hyperpolarized (13)C magnetic resonance spectroscopic imaging |
| Q35587235 | Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations |
| Q39796059 | Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. |
| Q28535039 | NETRIN-4 protects glioblastoma cells FROM temozolomide induced senescence |
| Q92035420 | PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival |
| Q38720885 | Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy |
| Q34631627 | Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy |
| Q37660266 | Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation |
| Q42120404 | Probing the PI3K/Akt/mTor pathway using (31)P-NMR spectroscopy: routes to glycogen synthase kinase 3. |
| Q28484418 | Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition |
| Q36658324 | Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy |
| Q52582181 | Synergistic anti-proliferative effect of mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity. |
Search more.